» Articles » PMID: 26857144

Lithium Inhibits Tumor Lymphangiogenesis and Metastasis Through the Inhibition of TGFBIp Expression in Cancer Cells

Overview
Journal Sci Rep
Specialty Science
Date 2016 Feb 10
PMID 26857144
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Metastasis is the main cause of mortality in cancer patients. Although there are many anti-cancer drugs targeting tumor growth, anti-metastatic agents are rarely developed. Angiogenesis and lymphangiogenesis are crucial for cancer progression; in particular, lymphangiogenesis is pivotal for metastasis in cancer. Here we report that lithium inhibits colon cancer metastasis by blocking lymphangiogenesis. Lithium reduces the expression of transforming growth factor-β-induced protein (TGFBIp) in colon cancer cells by inhibiting Smad3 phosphorylation via GSK3β inactivation. Moreover, lithium inhibits lymphatic endothelial cell migration, which is increased upon TGFBIp expression in tumor cells. Lithium had no significant effect on SW620 tumor growth in vitro and in vivo; however, it inhibited lymphangiogenesis in tumors. In tumor xenografts model, lithium was found to prevent metastasis to the lungs, liver, and lymph nodes by inhibiting TGFBIp-induced tumor lymphangiogenesis. Collectively, our findings demonstrate a novel role of lithium in the inhibition of colon cancer metastasis by blocking TGFBIp expression, and thereby TGFBIp-induced lymphangiogenesis, in primary tumors.

Citing Articles

Overcoming Chemotherapy Resistance in Metastatic Cancer: A Comprehensive Review.

Eslami M, Memarsadeghi O, Davarpanah A, Arti A, Nayernia K, Behnam B Biomedicines. 2024; 12(1).

PMID: 38255288 PMC: 10812960. DOI: 10.3390/biomedicines12010183.


Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments.

Yuan Z, Li Y, Zhang S, Wang X, Dou H, Yu X Mol Cancer. 2023; 22(1):48.

PMID: 36906534 PMC: 10007858. DOI: 10.1186/s12943-023-01744-8.


Lithium: A Promising Anticancer Agent.

Villegas-Vazquez E, Quintas-Granados L, Cortes H, Carmen M, Leyva-Gomez G, Rodriguez-Morales M Life (Basel). 2023; 13(2).

PMID: 36836894 PMC: 9966411. DOI: 10.3390/life13020537.


Lithium in Cancer Therapy: Friend or Foe?.

Yang C, Zhu B, Zhan M, Hua Z Cancers (Basel). 2023; 15(4).

PMID: 36831437 PMC: 9954674. DOI: 10.3390/cancers15041095.


Li-Doped Bioactive Ceramics: Promising Biomaterials for Tissue Engineering and Regenerative Medicine.

Farmani A, Salmeh M, Golkar Z, Moeinzadeh A, Ghiasi F, Amirabad S J Funct Biomater. 2022; 13(4).

PMID: 36278631 PMC: 9589997. DOI: 10.3390/jfb13040162.


References
1.
Peng Z, Ji Z, Mei F, Lu M, Ou Y, Cheng X . Lithium inhibits tumorigenic potential of PDA cells through targeting hedgehog-GLI signaling pathway. PLoS One. 2013; 8(4):e61457. PMC: 3634073. DOI: 10.1371/journal.pone.0061457. View

2.
Chalecka-Franaszek E, Chuang D . Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A. 1999; 96(15):8745-50. PMC: 17587. DOI: 10.1073/pnas.96.15.8745. View

3.
Shamloo B, Chhabra P, Freedman A, Potosky A, Malin J, Smith S . Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysis. Drug Saf. 2012; 35(6):507-18. DOI: 10.2165/11597600-000000000-00000. View

4.
Shi Y, Massague J . Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003; 113(6):685-700. DOI: 10.1016/s0092-8674(03)00432-x. View

5.
Schotte P, van Loo G, Carpentier I, Vandenabeele P, Beyaert R . Lithium sensitizes tumor cells in an NF-kappa B-independent way to caspase activation and apoptosis induced by tumor necrosis factor (TNF). Evidence for a role of the TNF receptor-associated death domain protein. J Biol Chem. 2001; 276(28):25939-45. DOI: 10.1074/jbc.M104014200. View